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Elevated levels of c-Src tyrosine kinase activity have been docu-
mented in several types of human primary cancers, and particularly in
colorectal cancer (Ottenhoff-Kalff et al, 1992; Talamonti et al, 1993).
Thus, activated expression of c-Src, a cellular human proto-oncogene
homologous to the v-src gene of Rous sarcoma virus, has been postu-
lated to play an important role in the development or progression of
human colon cancer (Mao et al, 1997). Recently, a novel activating
mutation of SRC (C to T transition at codon 531) has been described
in 12% of advanced human colorectal cancers from North America,
raising the possibility of a mutational activation of src kinase in these
tumours (Irby et al, 1999). The SRC 531 mutation has been then char-
acterized as activating, transforming, tumorigenic and metastasis-
promoting in experimental models. However, two subsequent studies
failed to detect any SRC 531 mutation in colorectal cancers from
Japanese and North European (Daigo et al, 1999), as well as from
Chinese (Wang et al, 2000) patients. Differences in ethnicity or in the
prevalence of advanced cancer between the individual series might
account for the observed discrepancy. 
The aim of our study was to look for SRC 531 mutations in a
large series of colorectal cancers from Italian patients, with a high
prevalence of metastatic tumours. 
MATERIALS AND METHODS 
Tissue specimens and DNA extraction 
To see at which time SRC 531 mutations could possibly occur
along the progression of colorectal cancer, we examined 119 tissue
specimens of primary colon cancer at different stages, and 52
samples of synchronous or metachronous liver metastases, for a
total of 155 cases (Table 1). All tissues were obtained from
Italian patients who had undergone surgical resection of
the primary tumour or of metastases at the Istituto Clinico
Humanitas between January 1997 and June 1999. Corresponding
normal tissue samples were always available. 
DNA extraction from paraffin-embedded tumour specimens
was carried out by digestion with Proteinase K (100 µg ml21)a t
37˚C for 12 h, followed by proteinase heat inactivation. 
PCR amplification and RFLP analysis 
A 149 bp amplicon of SRC exon 12 (GenBank accession K03218)
was obtained using the following primers: 5'-AGTGCTGGCG-
GAAGGAGCCT-3' (forward) and 5'-ATCCAAGCCGAGAAGC-
CGGT-3' (backward). The wild-type allele was amplified from
normal placental human DNA (human COT, Gibco Life
Technologies, Paisley, UK). PCR was run for 35 cycles, each cycle
consisting of denaturation at 94˚C for 30 s, annealing at 55˚C for
30 s and extension at 72˚C for 30 s. 
A ScaI-based RFLP-PCR assay was employed to detect the C to
T transition at the first base of codon 531 leading to AMBER muta-
tion. In the assay, only amplicons with the mutated TAG sequence
are cut by ScaI, their digestion resulting in two fragments of 90 and
59 bp, respectively. A positive control was PCR-generated using a
58-bp megaprimer containing the C to T transition at the first base
of codon 531 of SRC (from nucleotide 254 to nucleotide 197 of
K03218, with A instead of G at position 198). 
Digestion of amplicons was tested after overnight incubation
with 5 U of ScaI (New England Biolabs, Beverly, MA, USA). The
efficiency of the ScaI digestion in detecting variable amounts of
SRC531 mutated DNA was tested by assaying scalar ratios of
mutated to wild-type allele. 
RESULTS 
The ScaI RFLP assay detected the mutated allele when the ratio
between mutated and wild-type PCR products was 1:8 or higher
(Figure 1). 
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tissues included in the study (Table 1). The RFLP-PCR-assay
detected no SRC 531 mutation in any of the investigated tissues. A
non-digested product of 149 bp was always seen in gels from
normal tissues, primary colon cancers, and liver metastases.
Conversely, in each gel, the PCR-generated positive control for
enzyme digestion showed digested fragments of 90 and 59 bp,
respectively (Figure 2). 
Direct sequencing of several tumour samples confirmed
the presence of a wild-type codon 531, as opposed to the
AMBER mutation present in the PCR-generated positive control
(Figure 3). 
DISCUSSION 
By examining a total of 67 cases of metastatic colorectal cancer
(42 Dukes D at time of diagnosis and 25 metachronous liver
metastases, Table 1) for the presence of mutation in the primary
tumour and/or in the metastases, we expected to detect 5–8 cases
with SRC 531 mutation according to the originally reported preva-
lence of AMBER mutation in North American patients (Irby et al,
1999). In fact, no SRC 531 mutation was detected in any tissue of
our series (Figures 2 and 3). 
In their original report, Irby et al (1999) found high levels of
c-Src protein kinase activity in tissues positive at mutation
analysis, but they did not preselect tissues on this basis.
Therefore, the absence of mutations in our consecutive series of
late-stage colorectal cancers and liver metastases cannot be the
result of different criteria of selection. It is also unlikely that our
failure in detecting SRC 531 mutations may depend on tumour
sampling, since Irby et al claimed the genetic change to be clonal
in origin and present at multiple sites in each tumour. In addition,
the relative percentage of tumour cells in our tissues was always
higher than 50%, which, in case of heterozygous mutation,
would exceed a 1:4 ratio of mutant to wild-type allele. Thus,
negative results at the ScaI-based assay can be taken safely
(Figure 1), as long as the mutant and the wild-type alleles are
assumed to be equally amplified. At any event, a mutant allele-
specific test overcoming any preferential amplification of the
wild-type allele only confirmed mutations already identified at
the RFLP assay (Irby et al, 1999). 
As Daigo et al (1999) failed to find any genetic alterations at
codon 531 of human SRC in a large series of advanced colorectal
cancers from the Netherlands and from Japan, the hypothesis was
made that the SRC 531 mutation might be a mechanism of Src
activation in colon carcinogenesis only in a fraction of American
patients but not in other ethnically different populations (Daigo
et al, 1999). Along this line of investigation, Wang et al (2000)
recently reported no SRC 531 mutation in a series of colorectal
cancers from China. Besides ethnical differences, it must be
emphasized that both negative studies investigated series of
colorectal cancer with a prevalence of metastases lower than that
of the series studied by Irby et al (12% vs 63%). In our study,
metastatic colorectal cancers accounted for 43% of the entire
series, including 25 metachronous liver metastases. Thus, our
negative results conclusively demonstrate that the SRC 531
mutation does not confer any growth advantage and does not
contribute to clonal expansion or metastasis in colorectal cancer
from Italian patients. At this time, the cumulating negative
findings in ethnically different populations do question the real
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Table 1 Tumour tissues tested for the SRC 531 mutation and initial staging
of cancer (number of samples) 
Dukes stage at diagnosis 
AB C D  
Primary colorectal cancers (n = 119) 4 37 49 29 
Liver metastases (n = 52) 1 6 18a 27b
metachronous 
aTwo matched with primary CRC; b14 matched with primary CRC 
MW 1:1 1:2 1:4 1:8
Mut/WT ratio
149 bp
90 bp
59 bp
Figure 1 ScaI RFLP of codon 531-mutated SRC exon 12, in a scalar ratio
to wild-type. 90 and 59 bp digestion products are detectable up to a 1:8 ratio
of mutated-to-wild-type allele 
149 bp
90 bp
59 bp
T1 T2 T3 T4 C MWa MWb LM1 LM2 LM3 LM4
Figure 2 Agarose gel of RFLP-PCR products from advanced colorectal
cancers (T), and from liver metastases (LM). Digested fragments, evident
in the PCR-generated positive control (C), are not detectable in any 
tested sample. MW = molecular weight markers: a = 50 bp ladder;
b = øX174/Hind III 
CAG A G TACC C CCG C A G AG TACT CCC
Wild
type
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Figure 3 Direct sequencing of wild-type and mutated SRC exon 12 PCR
products. At codon 531, the mutation (C to T transition) seen in the
megaprimer-generated product, is not present in the PCR product from
cancer tissue (wild-type) 
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worldwide occurrence of SRC 531 mutation, even in a minor frac-
tion of advanced colon cancer. The possibility that in the original
study (Irby et al, 1999) an artificial mutation might have been
generated by a technical artifact, should be considered. If it is
obvious that such genetic alteration is of no use in identifying
patients with potentially metastatic disease, it is also extremely
unlikely that the mutation at codon 531 might even partially
explain the src activation commonly observed in advanced
colorectal cancer. To further investigate a possible c-Src genetic
activation in colorectal carcinogenesis, the entire c-Src gene
should be investigated for mutations, particularly in tumours with
high levels of tyrosine kinase activity. 
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